Orthotopic Heart Transplantation (OHT) is an appropriate treatment for patients with end-stage heart failure, as the beating heart is taken from a donor and will be implanted in the normal place of the recipient who has a high chance for post-transplantation recovery, improvement in quality of life, and survival. In recent decades, significant progress has been made in measures needed to control and assess transplant rejection and post-transplantation infections (Stengel et al., Heart 86(4):432–437, 2001). The first heart transplant surgery technique, described by Shumway, Lower, and Stofer, is known as biatrial anastomosis technique (BAAT) (Bolman., Oper Tech Thorac Cardiovasc Surg 4(2):98–113, 1999; Kitamura et al., Circ J 73(7):1235–1239, 2009), which was later replaced by bicaval anastomosis technique (mBCAT) (Locali et al., Arq Bras Cardiol 94(6):829–840, 2010). Other methods such as modified bicaval anastomosis technique (mBCAT) were developed by a group of Japanese heart surgeons as an appropriate heart transplant method (Bolman, Oper Tech Thorac Cardiovasc Surg 4(2):98–113, 1999). In the first year after OHT, graft rejection and infections are the most common causes of death, and often allograft vasculopathy and malignancy occur 5 years after cardiac transplant, whereas survival rate of patients following OHT has shown dramatic progress due to advances in surgical methods and improvements in the management of patients after OHT (Stehlik, J Heart Lung Transplant 29(10):1089–1103, 2010).